The establishment of a WHO Reference Reagent for anti-malaria (*Plasmodium falciparum*) human serum

Donna Bryan¹, Nilupa Silva¹, Peter Rigsby², Thomas Dougall², Patrick Corran¹, Paul W. Bowyer¹*, Mei Mei Ho¹*
and the Collaborative study group

Abstract

**Background:** At a World Health Organization (WHO) sponsored meeting it was concluded that there is an urgent need for a reference preparation that contains antibodies against malaria antigens in order to support serology studies and vaccine development. It was proposed that this reference would take the form of a lyophilized serum or plasma pool from a malaria-endemic area. In response, an immunoassay standard, comprising defibrinated human plasma has been prepared and evaluated in a collaborative study.

**Results:** A pool of human plasma from a malaria endemic region was collected from 140 single plasma donations selected for reactivity to *Plasmodium falciparum* apical membrane antigen-1 (AMA-1) and merozoite surface proteins (MSP-1₉₅, MSP-1₄₂, MSP-2 and MSP-3). This pool was defibrinated, filled and freeze dried into a single batch of ampoules to yield a stable source of naturally occurring antibodies to *P. falciparum*. The preparation was evaluated by an enzyme-linked immunosorbent assay (ELISA) in a collaborative study with sixteen participants from twelve different countries. This anti-malaria human serum preparation (NIBSC Code: 10/198) was adopted by the WHO Expert Committee on Biological Standardization (ECBS) in October 2014, as the first WHO reference reagent for anti-malaria (*Plasmodium falciparum*) human serum with an assigned arbitrary unitage of 100 units (U) per ampoule.

**Conclusion:** Analysis of the reference reagent in a collaborative study has demonstrated the benefit of this preparation for the reduction in inter- and intra-laboratory variability in ELISA. Whilst locally sourced pools are regularly use for harmonization both within and between a few laboratories, the presence of a WHO-endorsed reference reagent should enable optimal harmonization of malaria serological assays either by direct use of the reference reagent or calibration of local standards against this WHO reference. The intended uses of this reference reagent, a multivalent preparation, are (1) to allow cross-comparisons of results of vaccine trials performed in different centres/with different products; (2) to facilitate standardization and harmonization of immunological assays used in epidemiology research; and (3) to allow optimization and validation of immunological assays used in malaria vaccine development.

**Keywords:** *Plasmodium falciparum*, Malaria, Reference, Standardization, Serology, Vaccine, WHO Reference Reagent

**Background**

Malaria is a major public health problem with 91 countries, inhabited by a total of 3.4 billion people, with on-going malaria transmission. In 2015, there were approximately 212 million cases of malaria resulting in about 429,000 deaths, most of which were children under 5 years old [1].

A working group on laboratory methods for malaria vaccines under the auspices of the World Health Organization (WHO), Initiative for Vaccine Research (IVR), PATH Malaria Vaccine Initiative (MVI) and The National Institute of Allergy and Infectious Diseases (NIAID) agreed in a meeting held in September 2005, that an immunoassay standard for *Plasmodium falciparum*...
malaria antibodies was urgently needed to support vaccine development particularly in immunological assays development and standardization; also for harmonization of immunological assays used in epidemiology research of malaria [2]. It was proposed that this reference material would take the form of a lyophilized serum or plasma pool from a malaria-endemic area. The anti-malaria (P. falciparum) human serum reference reagent was considered as important in the progress of malaria vaccine development, especially in immunological assays development and standardization. WHO ECBS endorsed this proposal in 2005.

The reference reagent contains anti-malarial antibodies for multiple antigens and malaria species, but the initial standardization exercise concentrated on antibodies to P. falciparum apical membrane antigen-1 (AMA-1) and merozoite surface proteins (MSPs). This manuscript describes the collection, production and evaluation of this plasma pool leading to the establishment of the first International Reference Reagent for anti-malaria (Plasmodium falciparum) human serum as well as a further study describing the presence of anti-CSP antibodies and the range of anti-MSP-119 antibodies from different malaria species.

**Methods**

**Protein antigens**

*Escherichia coli*-derived: EcMSP3 (FVO), EcMSP-142 (3D7), EcMSP-142 (FUP), EcMSP-142 (FVO) and *Pichia pastoris*-derived: Pp AMA1 (3D7), PpAMA1 (FVO), PpAMA1 (L32) PpCSP-M3 (3D7) proteins were obtained from the Malaria Vaccine Development Branch, NIAID/NIH, Rockville, MD 20852, USA.

Recombinant MSP-119 from *P. falciparum*, *Plasmodium vivax*, *Plasmodium malariae* and *Plasmodium ovale* was obtained from The European Malaria Reagent Repository (http://www.malariaresearch.eu).

**Donation of plasma samples**

A proposal to collect malaria reactive plasma samples was developed and approved by the ethical boards of CDC and KEMRI and the Kenyan National Blood Bank Transfusion Services (KNBTS), and agreed by the Chief Medical Officer (CMO), Kenya Ministry of Health. As a result, in 2009, 140 plasma samples (20–50 ml volume and malaria reactive) were collected, screened for HIV, HBV and HCV by the blood bank, CDC, Kisumu, and sent to NIBSC, U.K. by the KEMRI/CDC.

**Lyophilization of anti-malaria defibrinated plasma pool (10/198)**

At NIBSC, the plasma samples were initially screened by ELISA against five *P. falciparum* antigens; AMA-1, MSP-119, MSP-142, MSP-2 and MSP-3. Samples with high titre anti-AMA-1 were pooled into four groups and defibrinated. The resulting serum was pooled, diluted 1:5 with sterile distilled water without any other excipients and filtered (1.2, 0.45 then 0.22 μm). No other buffer, bulking agent or stabilizer was used. The definitive fill was performed within the Standards Processing Division of NIBSC using a Bausch & Strobel Filling Machine (AFV5090). The diluted serum preparation was stirred constantly during filling to ensure homogeneity of fill and the temperature was maintained between 4 and 8 °C. DIN clear glass ampoules with capacity of 5 ml volume were used. Freeze-drying was performed using a 4-day cycle and the finished product was coded 10/198 and stored in the dark at −20 °C except for a small number of ampoules used for an accelerated degradation study.

A single batch of about 5000 ampoules was produced. The ampoules have an average actual fill weight of 1.0085 g per ampoule; with a target CV of precision of filling for fill mass of <0.25%, where the actual CV of fill mass was 0.11% (of 195 randomly selected ampoule, weights being measured). Nitrogen was used to back fill the freeze drier chamber at the end of the cycle and hence provide the headspace gas for the ampoules. The purity of the boiled off nitrogen was certified at 99.99%. Microbiological assessment was made on the product pre- and post-processing and the bacterial, mould, and yeast colony counts were negligible at pre- and post-filling stages. The residual moisture content of this preparation is 0.84% as determined by the Abderhalden method, with a CV of 12%. The mean oxygen head space was determined to be 0.34% with a CV of 20%. This was determined by taking a mean of 12 determinations using frequency modulation spectroscopy (FMS), a non-destructive infra-red laser absorption technique.

**Reference controls**

Three additional human serum preparations (as internal controls, C1, C2 or C3) representing different titres for anti-AMA-1 and anti-MSP-2 were also filled and lyophilized to be included as test samples in the collaborative study.

**Collaborative study design**

**Participants**

The candidate WHO Reference Reagent (Code: 10/198) was distributed to sixteen participating laboratories in twelve different countries (The Collaborative Study Group, see Acknowledgements). All invited participants were sent a questionnaire asking them to confirm having extensive experience in ELISA. The collaborative study involved a wide range of appropriately qualified laboratories representing clinical and research laboratories,
academia, not-for-profit research organizations, government-funded organizations and charitable organizations worldwide covering Africa, Asia, Europe and the USA. For this study, a code number was allocated at random to each participant.

**ELISA protocol for collaborative study**

Each participant was provided with 4 ampoules of positive control (XC) and 4 sets of nine blinded test samples (labelled with just the sample number) comprising coded duplicates of the 10/198 (coded S1 and S2 in this study) and internal controls. C1, C2 or C3 (see Table 1). The internal controls are also malaria reactive plasma pools from Kenya that were selected to provide a range of responses by ELISA thus ensuring a breadth of relative potencies for analysis in the collaborative study. Participants were requested to test nine blinded samples and a positive control as labelled using a specific study protocol. All ELISA plates included duplicates of 10/198 which were coded as ‘S1’ (sample numbers 1, 4 and 8) or ‘S2’ (sample numbers 2, 6 and 9) for statistical analysis.

In brief, 96-well ELISA plates (Immuno 4, flatbottom) were coated with 50 µl of antigen (2 µg/ml) in coating buffer (1.59 g Na₂CO₃ + 2.93 g NaHCO₃ per litre in deionized water, pH 9.4–9.6). The coated plates were sealed and stored overnight at 4 °C. After 3 washes with PBS-0.05% Tween 20 (PBS-T) plates were blocked with 200 µl of 1% skimmed milk (w/v) in PBS-T (diluent buffer) for 3 h at room temperature. Plates were washed a further 3 times in PBS-T, followed by adding 100 µl of diluent buffer into all wells.

Test samples and controls were reconstituted in 1 ml deionized water and mixed. To Column 1, 50 µl of reconstituted test samples or XC was added in duplicate to each well. A threefold serial dilution was prepared in diluent buffer across the entire plate. Plates were sealed and stored overnight at 4 °C.

| Sample number | Product code | Product name      |
|---------------|--------------|-------------------|
| Control       | Pool 4       | Reference control (XC) |
| 1             | 10/198       | Reference Reagent (S1) |
| 2             | 10/198       | Reference Reagent (S2) |
| 3             | Pool 2       | Control 2 (C2)    |
| 4             | 10/198       | Reference Reagent (S1) |
| 5             | 12/192       | Reference Reagent (S3) |
| 6             | 10/198       | Reference Reagent (S2) |
| 7             | Pool 1       | Control 1 (C1)    |
| 8             | 10/198       | Reference Reagent (S1) |
| 9             | 10/198       | Reference Reagent (S2) |

Plates were washed 6 times in PBS-T and 100 µl HRP-conjugated rabbit anti-human IgG (DAKO, 1:5000 in diluent buffer) was added before incubation for 3 h at room temperature. Plates were washed a further 6 times before colour development by addition of 100 µl/well of OPD substrate solution prepared as per the manufacturers instruction. The reaction was stopped by addition of 25 µl/well 2 M H₂SO₄ and absorbance at 492 nm was measured using a plate reader.

Participants were asked to perform three independent experiments on each set of samples, for three different coating antigens, using freshly reconstituted ampoules on each experimental day. For each experimental day a total of 27 antigen-coated plates were required for the three different antigens (MSP3, MSP-142 and AMA-1 3D7; i.e. 9 plates per antigen). The plate layout was such that each ELISA plate would generate results for two individual samples of 10/198 (S1 and S2), the positive control (XC) and an internal control (C1, C2 or C3).

All raw data from participants were sent and collated at NIBSC for statistical analysis.

**Stability studies**

The stability studies were performed at NIBSC only. Two independent ELISA experiments (as above) were performed for each antigen; three individual ampoules of each sample group were tested for each experiment.

Accelerated thermal degradation: ampoules of the 10/198 were stored at −150, −70, −20, 4, 20, 37, 45, or 56 °C, for 1, 3, 6, 9, 12, 18, or 24 months. At each time point the ampoules stored at the various temperatures were transferred to storage at −20 °C until further analysis. The stability samples (stored at various temperatures and at the fixed time points) were reconstituted and assessed using the same ELISA method described as above and compared to 10/198 stored at −150 °C.

In use stability after reconstitution: Ampoules were reconstituted in deionized water and stored at 4 or −20 °C for 1 or 3 months. After storage the samples were analysed and compared to freshly opened and reconstituted samples in the ELISA assay.

**Statistical analysis**

The potencies of all samples were calculated relative to 10/198 (S1) for each antigen from each participant laboratory by analysis of the raw optical density assay data. Log transformed absorbance values were used as the assay response in all cases. As a large volume of data of varying quality was received, full curves were not fitted and analysis was based only on an approximately linear section of the response range by excluding serum dilutions with responses falling outside 20–80% of the response range observed on the plate. Where this gave
The absorbance background values at 620 nm were subtracted in absorbance mode at 450 and 620 nm. Assays were combined to generate an unweighted geometric mean for each sample. Variability between laboratories and samples (p < 0.05 used to conclude significance).

Cross reactivity with other antigens

The cross reactivity of 10/198 with circumsporozoite protein (CSP) or MSP-1_{19} from different malaria species (P. falciparum, P. vivax, P. ovale or P. malariae) was investigated by ELISA (as above with few modifications). These experiments were performed at NIBSC only.

CSP ELISA; ELISA plates were coated at 2 µg/ml PpCSP in coating buffer overnight at 4 °C. Casien (1% w/v in PBS-T) was used as the blocking agent. TMB (100 µl) was used as peroxidase substrate for colour reaction which was stopped after 20 min by addition of 50 µl 1 M H_{2}SO_{4}. Plates were read on a Multiskan EX plate reader (Thermofisher) in absorbance mode at 450 and 620 nm. The absorbance background values at 620 nm were subtracted from those at 450 nm. In addition OD from negative control wells (no antigen) were subtracted from the OD of experimental samples.

In addition the intended use of 10/198 was demonstrated for potency evaluation of several test samples. These additional test samples (sample 23, 25 or 34) were from malaria reactive plasma packs stored at NIBSC. The data were analysed using CombiStats ver 5.0 (http://combistats.edqm.eu/) with a sigmoid curves model to determine potencies of the test samples relative to 10/198.

Competitive MSP-1_{19} ELISA was conducted similar to previous reports for mixed AMA-1 alleles [5] and was divided into two stages using 2 µg/ml of species specific recombinant MSP-1_{19} (Pf, Pm, Pv, Po) as coating antigens. In Stage one, a tritration of 10/198 was conducted to establish an optimal dilution factor that achieves a response in the approximately linear region of the dose response range (ca. 20–80%). This optimal dilution factor of 10/198 was then used in Stage two ELISA in the presence of the four recombinant MSP-1_{19} (at various concentrations). In brief, the plate was coated and blocked as before (2 µg/ml antigen) and then varying concentrations of competitor MSP-1_{19} (50 µl) was added in twofold dilution across a 96-well plate to deliver a highest concentration of 30 µg/ml MSP-1_{19} (from each of the species). This was followed by the 10/198 at the optimal dilution determined in stage one. The remainder procedure of the ELISA was performed as previously described.

Results and discussion

Data returned from study participants

The analysis of 10/198 was conducted by 16 different laboratories, data from a total of 1227 ELISA plates were received for statistical analysis (409 per antigen type). Data from experiment 1 for Laboratory 3 were not analysed as the substrate used was not consistent with that used in experiments 2 and 3. No other such inconsistencies were reported. Analysis of the remaining assays as described above gave valid estimates of relative potency in 93.6, 92.1 and 92.7% of cases for AMA-1, MSP-1_{42} and MSP-3, respectively.

Relative potencies of S1 and S2

Relative potency estimates for the two individual ampoules of 10/198 (S1 and S2) are summarized in Additional file 1: Table S1. The agreement between potency estimates for S1 and S2 within plates can be assessed by calculation of the ratio of slopes for each test sample relative to S1. The samples were concluded to be non-parallel when the slope ratio was outside of the range 0.67–1.50 and no estimates were reported. Where potency estimates were calculated, EC_{50} estimates (concentration required to achieve a 50% response) were also determined in order to assess their variability within and between laboratories.

Relative potency and EC_{50} estimates from all valid assays were combined to generate an unweighted geometric mean (GM) for each laboratory and these laboratory means were used to calculate an overall unweighted geometric mean for each sample. Variability between assays within laboratories and between laboratories has been expressed using geometric coefficients of variation (GCV = (10^{s} − 1) × 100% where s is the standard deviation of the log_{10} transformed estimates). Analysis of variance with Duncan's multiple range test [4] using the log transformed potency estimates was used to compare laboratories and samples (p < 0.05 used to conclude significance).
significantly from those obtained in all other laboratories. This was the case for Laboratory 2 (sample XC, all antigens), Laboratory 3 (sample C1, MSP-3 antigen), Laboratory 4 (sample XC, all antigens; sample C3, AMA-1 and MSP-142 antigens) and Laboratory 13 (sample XC, MSP-3 antigen; sample C1, AMA-1 antigen; sample C2, AMA-1 and MSP-142 antigens). All overall means and GCVs are therefore shown both including and excluding Laboratories 2, 3, 4 and 13 (Additional file 1: Tables S2–S7).

Table 2 summarizes the inter-laboratory variations after exclusion of outliers and demonstrates the benefits of determining relative potency rather than using EC50 as an absolute measure of potency. The observed GCVs are higher if EC50 data were considered with a range of 46.6–82.7%. However, when relative potency (to reference reagent 10/198) is calculated the GCVs reduced considerably to 5.4–13.9%. Without the exclusion of outliers the same trend remains (GCV range 46.6–82.7% for EC50, 9.5–55.6% for relative potency, Additional file 1: Tables S1–S7). Similarly to the inter-laboratory data there is a reduction in the intra-laboratory variability when relative potency is used in place of EC50, albeit a smaller one.

Figure 1 shows box-histograms of the observed relative potency (when 10/198 is used as a reference reagent) and 1/EC50 for the four test samples (C1, C2, C3 and XC). In each case a reduction in the inter laboratory variations can be seen when relative potency is reported instead of 1/EC50. These data demonstrate the benefit of using 10/198 as a common reference reagent across assays and laboratories.

Reference reagent 10/198 is stable at elevated temperature and after reconstitution
The reference reagent 10/198 has been lyophilized to maximize the long-term stability for storage and shipment. The thermal stability was assessed in a degradation study at elevated temperatures over a range of time points. The 24 month samples were analysed at NIBSC using the same ELISA protocol as in the collaborative study. The samples were readily reconstituted within 1 min, except for the ampoules stored at 56 °C, which required approximately 1–2 min instead to be fully reconstituted. Geometric mean potency estimates of samples stored at different temperatures for 24 months (expressed relative to those stored at −150 °C) are shown in Fig. 2a. Statistical analysis indicated that there was no detectable loss of reactivity even at 45 °C for 24 months, for AMA-1, MSP-142 or MSP-3. At 56 °C for both MSP-142 and MSP-3 no loss of activity was seen. Based on these data there was insufficient degradation to predict a yearly loss for 10/198.

In use stability after reconstitution in deionized water was assessed at −20 or 4 °C for 1 or 3 months. By comparison to freshly reconstituted preparation there is no evidence of any significant loss in relative potency of reconstituted content after storage for 3 months (Fig. 2b).

The use of Reference Reagent 10/198 as a standard for the calibration of serology assays has resulted in a significant decrease in inter and intra-laboratory variations and thus demonstrates the benefit of using this reagent for standardization of P. falciparum serological experiments. Furthermore the lyophilized preparation shows no loss in reactivity under accelerated degradation conditions and is stable for up to 3 months after reconstitution at 4 °C or lower. The preparation is maintained under controlled storage conditions at NIBSC on behalf of WHO and is ready for worldwide distribution when requested.

Unitage proposal
There is currently no WHO International Standard/Reference Reagent of human antiserum for any species of malaria. As there is no suitable preparation with known unitage for the calibration of 10/198, it was proposed to WHO ECBS, and agreed by participants, that this the first WHO Reference Reagent for Anti-Malaria (P. falciparum) human serum contains an arbitrary unitage of 100 Units per ampoule.

Reference reagent 10/198 recognizes CSP of Plasmodium falciparum
The collaborative study was designed to test the suitability of 10/198 to act as a reference reagent for serology studies against P. falciparum antigens. The study assessed the binding of the reference serum to the merozoite antigens AMA-1, MSP-142 and MSP3. However, the most advanced malaria vaccine candidate RTS,S is targeted against the pre-erythrocytic antigen, CSP. In July 2015 the vaccine candidate RTS,S/AS01 received a positive scientific opinion from the European Medicines Agency for the prevention of malaria in children aged 6 weeks to 17 months in sub-Saharan Africa [5].
Therefore, a separate investigation at NIBSC sought to determine if 10/198 could act as a reference reagent for detecting other malarial antigens. The reactivity of 10/198 to a recombinant CSP produced in *Pichia* was evaluated. Figure 3 shows that 10/198 is able to recognize CSP in a similar ELISA protocol as used in the collaborative study and, as a demonstration, this reference reagent was used to assign units to three plasma samples based
on the designation of 10/198. Figure 3 shows sample 23 had a relative potency of 22.7 U/ml (95% CL 13.8–37.5), considerably less potent than 10/198 while samples 25 and 34 had values of 462.8 (95% CL 404.9–529.0) and 1653.1 (95% CL 1283.8–2128.5) U/ml. These data demonstrate that 10/198 also contains antibodies recognizing CSP and could be of beneficial as a reference reagent beyond the scope of the antigens tested in the collaborative study.

Reference plasma 10/198 binds to PmMSP\textsubscript{19} and PoMSP\textsubscript{19} but not PvMSP\textsubscript{19}. It was also expected that 10/198, which was prepared from a pool of plasma samples from a malaria-endemic area, may contain antibodies from malaria species other than \textit{P. falciparum}. To investigate this, ELISA was performed using recombinant MSP-1\textsubscript{19} from each of \textit{P. falciparum}, \textit{P. vivax}, \textit{P. malariae} and \textit{P. ovale}. The relative titre of antibodies to each of these antigens is shown in Fig. 4. These data indicate 10/198 has significant reactivity with \textit{P. malariae} MSP-1\textsubscript{19} and \textit{P. ovale} MSP-1\textsubscript{19} but no significant reactivity with \textit{P. vivax} MSP-1\textsubscript{19} as could be expected with plasma samples collected in East Africa. Competitive ELISA (Fig. 4b) was used to investigate the species specificity of the binding to each individual MSP-1\textsubscript{19}. 

![Diagram](image)

**Fig. 2** Reference reagent 10/198 is stable at elevated temperature for 24 months and after reconstitution. a Relative potency measured by ELISA, compared to storage at $-150 \, ^\circ\text{C}$, after 24 months storage. b Relative potency measured by ELISA, compared to freshly reconstituted 10/198, after storage of reconstituted content for 3 months.

![Graph](image)

**Fig. 3** Reference reagent 10/198 detects recombinant PpCSP in ELISA. Serum dilution (Log) vs absorbance (AU) was measured for 10/198 and three unknown samples by ELISA with PpCSP as the coating antigen. Each ampoule of 10/198 contains 100 Units as assigned unitage. Parallel line analysis of the data presented in a was used to derive the unitage assigned in test samples b.

| Sample | Estimate U/ml | 95% CL (lower) U/ml | 95% CL (upper) U/ml |
|--------|---------------|---------------------|---------------------|
| 23     | 22.7          | 13.8                | 37.5                |
| 25     | 462.8         | 404.9               | 529.0               |
| 34     | 1653.1        | 1283.8              | 2128.5              |
Only PfMSP-19 (at 30 µg/ml) was able to compete for binding when using PfMSP-19 as the coating antigen; with similar specificity for PmMSP-19 as evidenced by the residual signal reducing to nearly zero when only the homologous competitor was used. Some mixed competition was observed when *P. ovale* MSP-119 was used as the coating antigen with both PmMSP-19 and PoMSP-19 able to compete at 30 µg/ml. As a control for PvMSP-19 a lyophilized serum standard (71/281) was used, that was derived from a blood transfusion initially diagnosed as *P. vivax* malaria, but not characterized further (Additional file 1: Figure S1). These data demonstrate that the reference reagent 10/198 contains antibodies capable of recognizing MSP-119 from *P. malariae* and *P. ovale* as well as *P. falciparum*. This is not unexpected given the reference reagent is derived from a pool of malaria reactive samples from adults but with no additional knowledge of prior malaria exposure this cannot be unequivocally linked to *P. malariae* or *P. ovale* infection.

**Conclusions**

In October 2014, the WHO ECBS adopted this preparation (10/198) as the first WHO Reference Reagent of anti-malaria (*Plasmodium falciparum*) human serum with assigned an arbitrary unitage of 100 units (U) per ampoule [6, 7]. It is stored at NIBSC (Code Number 10/198) for distribution worldwide since 2015. This reference reagent should be particularly useful for inter-laboratory standardization and harmonization of immunological assays used in vaccine development and epidemiology. Analysis of reagent requests suggests a number of manufacturers and academic research groups are making use of the 10/198. It is expected that these are predominantly in the field of sero-epidemiology and
diagnostics development potentially reflecting a change from the expected primary use conceived at the initiation of this project.

This reference reagent, whilst evaluated in the collaborative study against a few selected antigens, is expected to be constitute a valuable reagent over a far wider range of antigens including CSP, the antigen in the malaria vaccine, Mosquirix. However, testing has revealed no significant levels of antibodies against Rh5, a leading blood stage vaccine candidate (Silk and Draper pers. comm).

The establishment of the first WHO Reference Reagent of anti-malaria (P. falciparum) human serum represents a pool of serum from Kenyan adults and is intended to act as a reference point for serological assays. It is expected that local, more geographically relevant, pools may be calibrated against this reference reagent as part of a broader standardization process.

In addition to use in serology assays this reagent represents a standard reflecting the antibody composition consistent with naturally acquired immunity and it is expected that it will be beneficial in the standardization of a range of functional immunoassays. Osier et al. recently demonstrated the activity of pooled human IgG from malaria exposed Kenyan adults in an opsonic phagocytosis assay [8], although there appears to be little growth inhibitory activity for 10/198, when reconstituted and applied to standard in vitro culture without further manipulation (Bowyer and Khatri unpublished data).

Additional file

Additional file 1. Supplemental figure and tables.

Authors’ contributions

PC: Conceived the study and developed the proposal. DB, NS, PWB, MMH and the collaborative study group: Experimental work and sampler/results collation. PR and TD: Study design and statistical analysis. DB, PWB and MMH: Drafted manuscript. All authors read and approved the final manuscript.

Author details

1 Bacteriology Division, MHRA-NIBSC, South Mimm's, Potters Bar, Hertfordshire EN6 3QG, UK, 2 Biostatistics Group, MHRA-NIBSC, South Mimm's, Potters Bar, Hertfordshire EN6 3QG, UK

Acknowledgements

We would like to thank the donors and the CDC blood bank in Kisumu, West Kenya for sourcing and supplying the plasma samples, without which this study could not have occurred. Special thanks go to Dr. David Narum and NIAID/NIH for their kind donations of purified malaria antigen preparations used in this study. MSP1_19 antigens were obtained from the European Malaria Reagent Repository.

Thanks also go to Dr. Margaret Oduor (Director, Kisumu Regional Transfusion Bank, Kisumu, Kenya); Dr. Simon Kariuchi (Director, KEMRI-CDC Research Institute, Kisumu) and Dr. Ya-Ping Shi (Head Clinical Immunology & Molecular Epidemiology Laboratory, Division of Parasitic Diseases, CDC) for their great help to initiate the project. We would like to thank NIBSC CBMR team for optimizing the lyophilization formulation, as well as the Standards, Production and Dispatch teams who performed the filling, freeze drying, coding and distribution of the candidate material.

Finally we would like to extend special thanks to all the laboratories and scientists who participated and contributed to this collaborative study, without which this study could not have been completed.

Collaborative study group:

Evelina Angov. USMWM-WRAIR, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
Ed Remarque. Department of Parasitology Biomedical Primate Research centre, Post Box 3306, 2280 GH Rijswijk. The Netherlands
Daniel Dodoo. Department of Immunology, Noguchi Memorial Institute of Medical Research, Accra, P.O. Box Lg 581, University of Ghana, Ghana
Chris Drakeley. Division of Immunology, Faculty of Infectious and Tropical Diseases, The London School of Hygiene and Medicine, Keppel St, London WC1E 7HT, UK
James Beeson, Linda Reiling, and Gaoqian Feng. Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia
A. Manjurano. National Institute for Medical Research (NIMR) PO BOX 1462 Mwanza, Tanzania
Simon Kariuki. KEMR/CDC, Off Busia Road, P.O. Box 1578, Kisumu-40100, Kenya
Francis Ndungu and Dr Faith Osier. Kenya Medical Research Institute, PO Box 230, 80108, Kitui, Kenya
Denise L. Doolan. Molecular Vaccinology Laboratory The Queensland Institute of Medical Research Courier address: 300 Herston Road, Herston, QLD 4006, Australia
A. Marjorano. National Institute for Medical Research (NIMR) PO BOX 1462 Mwanza, Tanzania
Simon Kariuki. KEMR/CDC, Off Busia Road, P.O. Box 1578, Kisumu-40100, Kenya

Consenting interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The proposal to collect malaria reactive plasma samples was developed and approved by the ethical boards of CDC and KEMRI and the Kenyan National Blood Bank Transfusion Services (RNBTs), and agreed by the Chief Medical Officer (CMO), Kenya Ministry of Health.

Funding

The Burnet Institute would like to acknowledge the receipt of financial support from the National Health and Medical Research Council, Australia, and the Operational Infrastructure Support Scheme of the Victorian State Government, Australia, without which they would be unable to participate in this study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. WHO. World malaria report. Geneva: World Health Organization; 2016.
2. WHO. Malaria Vaccine Evaluation Group meeting: optimizing and standardizing assays for vaccine evaluation—the road to a validated malaria assay. Bethesda: NIH; 2005.
3. Gaines Das RE, Tydeman M. Iterative weighted regression analysis of logit responses: a computer program for analysis of bioassays and immunoassays. Comput Programs Biomed. 1982;15:13–22.
4. Duncan DB. T-tests and intervals for comparisons suggested by the data. Biometrics. 1975;31:339–59.
5. First malaria vaccine receives positive scientific opinion from EMA. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/07/news_detail_002376.jsp&mid=WC0b01ac058004d5c1.
6. Bryan D, Silva N, Rigsby P, Dougall T, Conan P, Ho MM. International collaborative study to evaluate and establish the 1st WHO Reference Reagent for Anti-Malaria (Plasmodium falciparum) human serum. WHO/BS/20142235; 2014.
7. Instructions for use. http://www.nibsc.org/documents/ifu/10-198.pdf.
8. Osier FHA, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med. 2014;12:108.